Drug Trial Radar · NCT05125224
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163,720
Actual
Start
Oct 1, 2021
Primary completion
Jul 7, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA); Rutgers University; Johns Hopkins University
- First posted
- Nov 18, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
Summary
As written by the sponsor on the registry.
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Conditions
- Hypertension
Interventions
Dihydropyridine calcium channel blockerDrug
Dihydropyridine calcium channel blocker claim is used as the exposure group.
HydrochlorothiazideDrug
Hydrochlorothiazide claim is used as the reference group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Dementia OnsetTime frame: Median follow up times: 1) 189 days (exp), 171 days (ref) 2) 835 days (exp). 851 days (ref) 3) 388 days (exp), 348 days (ref) 4) 191 days (exp), 172 days (ref)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.